Key takeaways:

Nasal polyp and congestion scores dropped more with stapokibart vs. placebo.

Overall nasal symptoms, sense of smell and 22-item Sino-Nasal Outcome Test score also significantly improved in the stapokibart group.

Perspective from Monica T. Kraft, MD

Receiving the novel monoclonal antibody stapokibart for 24 weeks lowered polyp size and nasal symptom severity vs. placebo in adults with severe chronic rhinosinusitis with nasal polyps, according to results published in JAMA .

In the randomized, double-blind, phase 3 CROWNS-2 clinical trial, Shen Shen , MS, and colleagues evaluated 179 adults (mean age, 45 years; 34.1% women) with severe uncontrolled CRSwNP in China to determine how stapokibart (Keymed Biosciences) added on to intranasal corticosteroids impac

See Full Page